BioSpace News Archive

Bio-Techne has further added to its cell therapy portfolio by expanding the range of Tocris Bioscience-branded cGMP small molecules to include the commonly used stem cell compounds, Y-27632 (ROCK inhibitor) and CHIR 99021.

-- Pilot study to evaluate use of Cofactor assay in Genocea’s neoantigen vaccine clinical trial --

The vegan movement is gaining momentum as Veganuary expands across the pond from the United Kingdom to the United States.

Decorated clinician oversaw most extensive FDA trials on sexual dysfunction drugs Viagra® and Cialis®; Brings 25-year medical experience to launch novel cannabinoid-based sexual health and wellness line focused on performance and pleasure enhancement for men and women

Kindbody, a company building women’s health clinics starting in New York City and San Francisco, is announcing the hire of Dr. Lynn Westphal from Stanford Medical School as Chief Medical Officer, Reproductive Endocrinology.

Integral Molecular, the industry leader in antibody discovery against multipass membrane proteins, was awarded $1.4M by the NIH to develop its lead antibodies against cannabinoid receptor 1 (CB1) for treating the liver disease nonalcoholic steatohepatitis (NASH) and metabolic disorders, including obesity and metabolic syndrome.

A collaboration with HealthStream will provide innovative curriculum to Healthcare market

Arrevus Inc. received a $300,000 STTR grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) to develop a compound library and screening platform of DnaK inhibitors, a new class of anti-infectives to treat antibiotic resistant infections.

PharmaCyte Biotech, Inc. today announced that it has engaged cGMP Validation L.L.C. (cGMP Validation) to assist in the preparation of the Investigational New Drug application (IND) that must be submitted to and approved by the U.S. Food and Drug Administration (FDA) before PharmaCyte can begin its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC).

Journal of Surgical Research published study shows that reductions in surgical site infection (SSI) lead to substantial cost savings for hospitals